Table 3.
Baseline characteristics in four groups with different TyG levels.
| Variables | Group 1 (n 232) | Group 2 (n = 232) | Group 3 (n = 232) | Group 4 (n = 232) | P-value |
|---|---|---|---|---|---|
| Baseline data | |||||
| Male (n, %) | 170 (73.3%) | 162 (69.8%) | 169 (72.8%) | 157 (67.7%) | 0.501 |
| Age (years) | 70.60 ± 9.15 | 69.01 ± 8.79 | 70.80 ± 7.81 | 63.21 ± 7.50 | <0.001* |
| SBP (mmHg) | 135.34 ± 20.04 | 135.49 ± 17.99 | 136.86 ± 16.00 | 140.83 ± 17.60 | <0.001* |
| DBP (mmHg) | 74.99 ± 10.43 | 74.25 ± 9.54 | 75.47 ± 13.74 | 81.87 ± 12.59 | <0.001* |
| BMI (kg/m2) | 25.44 ± 3.17 | 24.47 ± 5.70 | 24.03 ± 5.34 | 24.13 ± 4.62 | 0.260 |
| Hypertension (n, %) | 178 (72.4%) | 184 (79.3%) | 177 (72.0%) | 202 (85.8%) | 0.013 |
| Hypotension (n, %) | 2 (0.9%) | 3 (1.3%) | 5 (2.2%) | 4 (1.7%) | 0.694 |
| Anemia (n, %) | 4 (1.7%) | 2 (0.9%) | 1 (0.4%) | 0 (0.0%) | 0.169 |
| CKD (n, %) | 8 (3.4%) | 4 (1.7%) | 6 (2.6%) | 1 (0.4%) | 0.124 |
| Hydration (n, %) | 187 (80.8%) | 191 (82.6%) | 180 (77.6%) | 178 (76.7%) | 0.409 |
| CI-AKI | 7 (3%) | 35 (15.1%) | 66 (28.4%) | 89 (38.4%) | <0.001* |
| Coronary angiography | |||||
| PCI (n, %) | 165 (69.4%) | 161 (66.8%) | 166 (71.6%) | 178 (76.7%) | 0.112 |
| Dose of contrast agent P50 (P25–P75) (ml) |
69 (45–83) | 70 (50–92) | 72 (50–92) | 65 (50–92) | 0.673 |
| Number of lesion vessels | 1.79 ± 0.64 | 1.65 ± 0.91 | 1.73 ± 0.54 | 1.52 ± 0.87 | 0.341 |
| Number of stents | 0.81 ± 0.34 | 1.02 ± 0.54 | 1.01 ± 0.48 | 0.92 ± 0.49 | 0.116 |
| Hematological index | |||||
| Preoperative eGFR P50
(P25–P75) (ml/min/1.73m2) |
87.6 (78.7–92.4) | 85.7 (75.5–89.0) | 84.7 (77.5–86.9) | 86.5 (80.6–88.3) | 0.329 |
| FBG P50 (P25–P75) (mmol/L) | 6.12 (4.94–6.35) | 7.08 (5.90–8.33) | 7.93 (6.79–9.00) | 8.47 (7.19–12.06) | <0.001* |
| HbAlc (%) | 7.60 ± 1.76 | 7.37 ± 1.46 | 7.47 ± 1.57 | 8.06 ± 1.60 | <0.001* |
| Triglyceride P50
(P25–P75) (mmol/L) |
0.69 (0.85–1.10) | 1.16 (1.07–1.40) | 1.68 (1.33–1.93) | 2.74 (2.05–4.35) | <0.001* |
| TC P50
(P25–P75) (mmol/L) |
3.42 (3.00–3.74) | 3.91 (3.32–4.4) | 4.05 (2.66–5.06) | 4.65 (3.93–5.54) | <0.001* |
| HDL-c | 1.18 (1.01–1.29) | 1.11 (0.99–1.19) | 1.09(0.98–1.13) | 1.06 (0.93–1.10) | 0.052 |
| LDL-c | 2.05 (1.46–2.26) | 2.18 (1.83–2.77) | 2.52 (1.37–3.06) | 2.37 (1.72–3.28) | <0.001* |
| TyG index | 8.28 ± 0.29 | 8.83 ± 0.13 | 9.22 ± 0.13 | 10.05 ± 0.53 | <0.001* |
| Medications | |||||
| Oral hypoglycemic Drugs (n, %) |
203 (87.5%) | 205 (88.4%) | 212 (91.4%) | 220 (94.8%) | 0.030* |
| Insulin (n, %) | 61 (26.3%) | 63 (27.2%) | 68 (29.3%) | 72 (31.0%) | 0.667 |
| Aspirin | 207 (89.2%) | 211 (90.9%) | 217 (93.5%) | 215 (92.7%) | 0.347 |
| ACEI/ARB | 140 (60.3%) | 130 (56.0%) | 134 (57.8%) | 145 (62.5%) | 0.506 |
| β-blocker | 195 (84.1%) | 192 (82.8%) | 205 (87.2%) | 192 (82.8%) | 0.29 |
| CCB | 115 (49.6%) | 114 (49.1%) | 123 (53.0%) | 142 (61.2%) | 0.033* |
| Statin | 222 (95.7%) | 230 (99.1%) | 229 (98.7%) | 227 (97.8%) | 0.051 |
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; CKD, chronic kidney dysfunction; CI-AKI, contrast induced-acute kidney injury; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; TyG, triglyceride-glucose; eGFR, estimated glomerular filtration rate; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.
* represents P < 0.05.